[1]
|
熊雪松, 余显霞. 2型糖尿病与骨质疏松症相关性研究进展[J]. 中国骨质疏松杂志, 2017, 23(1): 130-135.
|
[2]
|
Li, Y.Z., Teng, D., Shi, X.G., et al. (2020) Prevalence of Diabetes Recorded in Mainland China Using 2018 Diagnostic Criteria from the American Diabetes Association: National cross Sectional Study. British Medical Journal, 369, m997.
https://doi.org/10.1136/bmj.m997
|
[3]
|
Notarnicola, A., et al. (2016) Epidemiology of Diabetes Mellitus in the Fragility Fracture Population of a Region of Southern Italy. Journal of Biological Regulators and Homeostatic Agents, 30, 297-302.
|
[4]
|
Junk, J.K., et al. (2012) Fracture Incidence and Risk of Osteoporosis in Female Type 2 Diabetic Patients in Korea. Diabetes & Metabolism Journal, 36, 144-150. https://doi.org/10.4093/dmj.2012.36.2.144
|
[5]
|
de Liefde, I.I., van der Klift, M., de Laet, C.E., van Daele, P.L., Hofman, A. and Pols, H.A. (2005) Bone Mineral Density and Fracture Risk in Type-2 Diabetes Mellitus: The Rotterdam Study. Osteoporosis International, 16, 1713-1720.
https://doi.org/10.1007/s00198-005-1909-1
|
[6]
|
Ottenbacher, K.J., Ostir, G.V., Peek, M.K., Goodwin, J.S. and Markides, K.S. (2002) Diabetes Mellitus as a Risk Factor for Hip Fracture in Mexican American Older Adults. The Journals of Gerontology Series A. Biological Sciences and Medical Sciences, 57, M648-M653.
|
[7]
|
Strotmeyer, E.S., Cauley, J.A., Schwartz, A.V., et al. (2005) Nontraumatic Fracture Risk with Diabetes Mellitus and Impaired Fasting Glucose in Older White and Black Adults: The Health, Aging, and Body Composition Study. Archives of Internal Medicine, 165, 1612-1617. https://doi.org/10.1001/archinte.165.14.1612
|
[8]
|
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版) [J]. 中华糖尿病杂志, 2021, 13(4): 315-409.
|
[9]
|
Viscoli, C.M., Inzucchi, S.E., Young, L.H., et al. (2017) Pioglitazone and Risk for Bone Fracture. Safety Data from a Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism, 102, 914-922.
|
[10]
|
Ye, Y.L., Zhao, C.H., Liang, J., et al. (2018) Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Bone Metabolism and Fracture Risk. Frontiers in Pharmacology, 9, Article No. 1517. https://doi.org/10.3389/fphar.2018.01517
|
[11]
|
Lecka-Czernik, B. (2017) Diabetes, Bone and Glucose-Lowering Agents: Basic Biology. Diabetologia, 60, 1163-1169.
https://doi.org/10.1007/s00125-017-4269-4
|
[12]
|
Mai, Q.G., Zhang, Z.M., Xu, S., et al. (2011) Metformin Stimulates Osteoprotegerin and Reduces RANKL Expression in Osteoblasts and Ovariectomized Rats. Journal of Cellular Biochemistry, 112, 2902-2909.
https://doi.org/10.1002/jcb.23206
|
[13]
|
Schurman, L., McCarthy, A.D., Sedlinsky, C., et al. (2008) Metformin Reverts Deleterious Effects of Advanced Glycation End-Products (AGEs) on Osteoblastic Cells. Experimental and Clinical Endocrinology and Diabetes, 116, 333-340.
|
[14]
|
Starup-Linde, J., Gregersen, S., Frost, M., et al. (2017) Use of Glucose-Lowering Drugs and Risk of Fracture in Patients with Type 2 Diabetes. Bone, 95, 136-142.
|
[15]
|
Monami, M., Cresci, B., Colombini, A., et al. (2008) Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients: A Case-Control Study. Diabetes Care, 31, 199-203. https://doi.org/10.2337/dc07-1736
|
[16]
|
Campbell, J.E. and Drucker, D.J. (2013) Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. Cell Metabolism, 17, 819-837.
|
[17]
|
Nuche-Berenguer, B., Moreno, P., Portal-Núñez, S., et al. (2010) Exendin-4 Exerts Osteogenic Actions in Insulin-Resistant and Type 2 Diabetic States. Regulatory Peptides, 159, 61-66.
|
[18]
|
Nuche-Berenguer, B., Portal-Núñez, S., Moreno, P., et al. (2010) Presence of a Functional Receptor for GLP-1 in Osteoblastic Cells, Independent of the cAMP-Linked GLP-1 Receptor. Journal of Cellular Physiology, 225, 585-592.
https://doi.org/10.1002/jcp.22243
|
[19]
|
Ma, X., Meng, J.R., Jia, M., et al. (2013) Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Prevents Osteopenia by Promoting Bone Formation and Suppressing Bone Resorption in Aged Ovariectomized Rats. Journal of Bone and Mineral Research, 28, 1641-1652. https://doi.org/10.1002/jbmr.1898
|
[20]
|
Papazafiropoulou, A., Papanas, N., Pappas, S., et al. (2014) Role of Endogenous GLP-1 and Its Agonists in Osteopenia and Osteoporosis: But We Little Know Until Tried. Current Diabetes Reviews, 10, 43-47.
https://doi.org/10.2174/1573399810666140217114848
|
[21]
|
Bunck, M.C., Eliasson, B., Cornér, A., et al. (2011) Exenatide Treatment Did Not Affect Bone Mineral Density Despite Body Weight Reduction in Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 13, 374-377.
https://doi.org/10.1111/j.1463-1326.2010.01355.x
|
[22]
|
Monami, M., Dicembrini, I., Antenore, A., et al. (2011) Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A Meta-Analysis of Randomized Clinical Trials. Diabetes Care, 34, 2474-2476. https://doi.org/10.2337/dc11-1099
|
[23]
|
Hegazy, S.K. (2015) Evaluation of the Anti-Osteoporotic Effects of Metformin and Sitagliptin in Postmenopausal Diabetic Women. Journal of Bone and Mineral Metabolism, 33, 207-212. https://doi.org/10.1007/s00774-014-0581-y
|
[24]
|
Bunck, M.C., Poelma, M., Eekhoff, E.M., et al. (2012) Effects of Vildagliptin on Postprandial Markers of Bone Resorption and Calcium Homeostasis in Recently Diagnosed, Well-Controlled Type 2 Diabetes Patients. Journal of Diabetes, 4, 181-185. https://doi.org/10.1111/j.1753-0407.2011.00168.x
|
[25]
|
Sbaraglini, M.L., Molinuevo, M.S., Sedlinsky, C., et al. (2014) Saxagliptin Affects Long-Bone Microarchitecture and Decreases the Osteogenic Potential of Bone Marrow Stromal Cells. European Journal of Pharmacology, 727, 8-14.
https://doi.org/10.1016/j.ejphar.2014.01.028
|
[26]
|
Ma, P., Gu, B., Ma, J., Lingling, E., Wu, X., Cao, J., et al. (2010) Glimepiride Induces Prolife Ration and Differentiation of Rat Osteoblasts via the PI3-Kinase/Akt Pathway. Metabolism, 59, 359-366.
|
[27]
|
Fronczek-Sokół, J. and Pytlik, M. (2014) Effect of Glimepiride on the Skeletal System of Ovariectomized and Non-Ovariectomized Rats. Pharmacological Reports, 66, 412-417. https://doi.org/10.1016/j.pharep.2013.12.013
|
[28]
|
Ma, P., Xiong, W., Liu, H.C., Ma, J.L., Gu, B. and Wu, X. (2011) Extrapancreatic Roles of Glimepiride on Osteoblasts from Rat Manibular Bone in Vitro: Regulation of Cytodifferentiation through PI3-Kinases/Akt Signalling Pathway. Archives of Oral Biology, 56, 307-316. https://doi.org/10.1016/j.archoralbio.2010.10.009
|
[29]
|
Kanazawa, I., Yamaguchi, T., Yamamoto, M. and Sugimoto, T. (2010) Relationship between Treatments with Insulin and Oral Hypoglycemic Agents versus the Presence of Vertebral Fractures in Type 2 Diabetes Mellitus. Journal of Bone and Mineral Metabolism, 28, 554-560. https://doi.org/10.1007/s00774-010-0160-9
|
[30]
|
Adila, M., Ali Khana, R., Kalama, A., Venkatab, S.K., Kandhareb, A.D., Ghoshb, P. and Sharmaa, M. (2017) Effect of Anti-Diabetic Drugs on Bone Metabolism: Evidence from Preclinical and Clinical Studies. Pharmacological Reports, 69, 1328-1340. https://doi.org/10.1016/j.pharep.2017.05.008
|
[31]
|
Thomas, D., Ng, K. and Insulin Best, J. (1997) Bone: A Clinical and Scientific Review. Endocrinology and Metabolism, 4, 5-17.
|
[32]
|
Cornish, J., Callon, K. and Reid, I. (1996) Insulin Increases Histomorphometric Indices of Bone Formation in Vivo. Calcified Tissue International, 59, 492-495.
|
[33]
|
Pastor, M.C., Lopez-Ibarra, P., Escobar-Jimenez, F., Pardo, M.S. and Garcia-Cervigon, A. (2000) Intensive Insulin Therapy and Bone Mineral Density in Type 1 Diabetes Mellitus: A Prospective Study. Osteoporosis International, 11, 455-459. https://doi.org/10.1007/s001980070114
|
[34]
|
Dennison, E.M., Syddall, H.E., Aihie Sayer, A., Craighead, S., Phillips, D.I. and Cooper, C. (2004) Type 2 Diabetes Mellitus Is Associated with Increased Axial Bone Density in Men and Women from the Hertfordshire Cohort Study: Evidence for an Indirect Effect of Insulin Resistance. Diabetologia, 47, 1963-1968.
https://doi.org/10.1007/s00125-004-1560-y
|
[35]
|
Melton, L.J., Leibson, C.L., Achenbach, S.J., Therneau, T.M. and Khosla, S. (2008) Fracture Risk in Type 2 Diabetes: Update of a Population-Based Study. Journal of Bone and Mineral Research, 23, 1334-1342.
https://doi.org/10.1359/jbmr.080323
|
[36]
|
Vestergaard, P., Rejnmark, L. and Mosekilde, L. (2005) Relative Fracture Risk in Patients with Diabetes Mellitus, and the Impact of Insulin and Oral Antidiabetic Medication on Relative Fracture Risk. Diabetologia, 48, 1292-1299.
https://doi.org/10.1007/s00125-005-1786-3
|
[37]
|
Mieczkowska, A., Baslé, M.F., Chappard, D. and Mabilleau, G. (2012) Thiazolidinediones Induce Osteocyte Apoptosis by a G Protein-Coupled Receptor 40-Dependent Mechanism. Journal of Biological Chemistry, 287, 23517-23526.
|
[38]
|
Mabilleau, G., Mieczkowska, A. and Edmonds, M. (2010) Thiazolidinediones Induce Osteocyte Apoptosis and Increase Sclerostin Expression. Diabetic Medicine, 27, 925-932. https://doi.org/10.1111/j.1464-5491.2010.03048.x
|
[39]
|
Ayus, J.C., Negri, A.L., Kalantar-Zadeh, K. and Moritz, M.L. (2012) Is Chronic Hyponatremia a Novel Risk Factor for Hip Fracture in the Elderly? Nephrology Dialysis Transplantation, 27, 3725-3731. https://doi.org/10.1093/ndt/gfs412v
|
[40]
|
Taylor, S.I., Blau, J.E. and Rother, K.I. (2015) Possible Adverse Effects of SGLT2 Inhibitors on Bone. The Lancet Diabetes & Endocrinology, 3, 8-10. https://doi.org/10.1016/S2213-8587(14)70227-X
|
[41]
|
Schwartz, A.V. (2017) Efficacy of Osteoporosis Therapies in Diabetic Patients. Calcified Tissue International, 100, 165-173. https://doi.org/10.1007/s00223-016-0177-8
|
[42]
|
Schwartz, A.V., Pavo, I., Alam, J., Disch, D.P., Schuster, D., Harris, J.M. and Krege, J.H. (2016) Teriparatide in Patients with Osteoporosis and Type 2 Diabetes. Bone, 91, 152-158. https://doi.org/10.1016/j.bone.2016.06.017
|
[43]
|
Murray, T.M. (1988) The Importance of Calcium in Osteoporosis Prevention. Official Position of the Osteoporosis Society of Canada. Osteoporosis Society of Canada Bulletin for Physicians, 1, 2-6.
|
[44]
|
Baeke, F., Gysemans, C., Korf, H., et al. (2010) Vitamin D Insufficiency: Implications for the Immune System. Pediatric Nephrology, 25, 1597-1606. https://doi.org/10.1007/s00467-010-1452-y
|
[45]
|
张永文. 糖尿病膳食指南八条建议[J]. 家庭医学(下), 2019(11): 26-27.
|
[46]
|
Colberg, S.R., Sigal, R.J., Yardley, J.E., et al. (2016) Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care, 39, 2065-2079. https://doi.org/10.2337/dc16-1728
|
[47]
|
邹冬梅, 冯平. 运动疗法对2型糖尿病老年患者骨质疏松情况的预防效果[J]. 基础医学与调查报告, 2020, 7(28): 281-282.
|
[48]
|
Qin, R., Chen, T., Lou, Q.Q., et al. (2013) Excess Risk of Mortality and Cardiovascular Events Associated with Smoking among Patients with Diabetes: Meta-Analysis of Observational Prospective Studies. International Journal of Cardiology, 167, 342-350.
|
[49]
|
刘凤娟, 周慧敏, 徐绍娟. 吸烟对老年男性糖尿病患者骨密度的影响[J]. 中国骨质疏松杂志. 2012, 18(9): 808-810.
|
[50]
|
张洪霞, 刘丽红, 龚雄辉. 吸烟对中年男性糖尿病患者骨含量影响的研究[J]. 现代中西医结合杂志, 2010, 19(4): 427-428.
|
[51]
|
姚坤, 侯丽艳, 姜丽平, 刘晓芳, 张聪, 汪源. 糖尿病性骨质疏松常见危险因素Meta分析[J]. 中国保健营养, 2019, 29(16): 8-9.
|
[52]
|
陈一萍, 李芳渊, 楼晓君, 陈锦平, 边平达. 老年男性吸烟与骨转换标志物、骨密度和骨质疏松性骨折风险的关系[J]. 全科医学临床与教育, 2021, 19(1): 15-17.
|
[53]
|
中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017) [J]. 中华内分泌代谢杂志, 2017, 33(10): 890-913.
|